Rubric Capital Management LP Lowers Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Rubric Capital Management LP decreased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 90.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,671 shares of the specialty pharmaceutical company’s stock after selling 547,129 shares during the quarter. Rubric Capital Management LP owned 0.27% of ANI Pharmaceuticals worth $3,381,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ANIP. Innealta Capital LLC acquired a new stake in ANI Pharmaceuticals during the second quarter valued at $65,000. Ridgewood Investments LLC acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $85,000. SG Americas Securities LLC purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at about $106,000. O Shaughnessy Asset Management LLC acquired a new position in ANI Pharmaceuticals in the 1st quarter worth about $218,000. Finally, XTX Topco Ltd purchased a new position in ANI Pharmaceuticals during the second quarter worth approximately $207,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ANIP shares. StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Piper Sandler started coverage on shares of ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective on the stock. Raymond James boosted their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. HC Wainwright restated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Finally, Truist Financial lifted their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $77.33.

ANI Pharmaceuticals Stock Down 1.3 %

NASDAQ:ANIP opened at $57.86 on Wednesday. The company’s 50-day moving average is $58.36 and its two-hundred day moving average is $60.83. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 1-year low of $48.20 and a 1-year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The firm had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm’s quarterly revenue was up 12.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.05 earnings per share. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.